A large meta-analysis of 45 RCTs recently found that compared with placebo or other interventions, GLP-1RAs did not increase the risk of thyroid cancer, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass, and goiter [69]
As of July 31, 2025, the FDA reported 605 adverse events linked to compounded semaglutide and 545 for compounded tirzepatide
doi: 10.3389/fendo.2025.1687601 Received 21 August 2025 Revised 29 October 2025 Accepted 20 November 2025 Published 05 December 2025 Volume 16 - 2025 Edited by Olorunfemi Raphael Molehin, Ekiti State University, Nigeria Reviewed by Dr
Heres a simple breakdown based on studies: Retatrutide: Side effects and safety considerations Retatrutide is still being studied, but clinical trials already give a helpful picture of what side effects people might experience
Coaching on nutrition, hydration, and habits to support sustainable results
Obes Surg (2008) 18(9):11837